心血管

订阅

MedSci主页 / 所有栏目 / 心血管

ESH发表RDN治疗难治性高血压立场文件

2012-04-17 高晓方（译） 医学论坛网

肾交感神经难治性高血压
关注

　　欧洲高血压学会（ESH）专家撰写了立场文件，以便就经皮腔内去肾交感神经术（percutaneous transluminal ablation of renal nerves ，RDN）的当前证据、未满足需求和临床推荐加以总结；RDN为治疗顽固性高血压的一种新型治疗策略。肾交感神经激活和中枢神经系统的感觉传入信号为RDN的靶点。临床研

　　欧洲高血压学会（ESH）专家撰写了立场文件，以便就经皮腔内去肾交感神经术（percutaneous transluminal ablation of renal nerves ，RDN）的当前证据、未满足需求和临床推荐加以总结；RDN为治疗顽固性高血压的一种新型治疗策略。肾交感神经激活和中枢神经系统的感觉传入信号为RDN的靶点。临床研究显示，基于导管的RDN可阻断传出交感和传入感觉神经通路，从而在顽固性高血压患者中实现具有临床意义的收缩压和舒张压降低。此项立场声明力图促进对仍有待明确的RDN的有效性、安全性、局限性和相关问题进行更深入了解。全文发表于《高血压杂志》[J Hypertens 2012, 30(5):837]。

　　 ESH立场文件链接： ESH Position Paper: Renal denervation - an interventional therapy of resistant hypertension.



    

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1522077, encodeId=542f15220e766, content=<a href='/topic/show?id=7989e00931' target=_blank style='color:#2F92EE;'>#ESH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7009, encryptionId=7989e00931, topicName=ESH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=877111409735, createdName=wfang549, createdTime=Thu Apr 19 02:56:00 CST 2012, time=2012-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528227, encodeId=b8c1152822eb9, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu Apr 19 02:56:00 CST 2012, time=2012-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538743, encodeId=42091538e436b, content=<a href='/topic/show?id=89ec1519928' target=_blank style='color:#2F92EE;'>#RDN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15199, encryptionId=89ec1519928, topicName=RDN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e013034210, createdName=xsm922, createdTime=Thu Apr 19 02:56:00 CST 2012, time=2012-04-19, status=1, ipAttribution=)]
    2012-04-19 wfang549

    #ESH#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1522077, encodeId=542f15220e766, content=<a href='/topic/show?id=7989e00931' target=_blank style='color:#2F92EE;'>#ESH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7009, encryptionId=7989e00931, topicName=ESH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=877111409735, createdName=wfang549, createdTime=Thu Apr 19 02:56:00 CST 2012, time=2012-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528227, encodeId=b8c1152822eb9, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu Apr 19 02:56:00 CST 2012, time=2012-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538743, encodeId=42091538e436b, content=<a href='/topic/show?id=89ec1519928' target=_blank style='color:#2F92EE;'>#RDN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15199, encryptionId=89ec1519928, topicName=RDN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e013034210, createdName=xsm922, createdTime=Thu Apr 19 02:56:00 CST 2012, time=2012-04-19, status=1, ipAttribution=)]
    2012-04-19 freve

    #难治性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1522077, encodeId=542f15220e766, content=<a href='/topic/show?id=7989e00931' target=_blank style='color:#2F92EE;'>#ESH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7009, encryptionId=7989e00931, topicName=ESH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=877111409735, createdName=wfang549, createdTime=Thu Apr 19 02:56:00 CST 2012, time=2012-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528227, encodeId=b8c1152822eb9, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu Apr 19 02:56:00 CST 2012, time=2012-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538743, encodeId=42091538e436b, content=<a href='/topic/show?id=89ec1519928' target=_blank style='color:#2F92EE;'>#RDN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15199, encryptionId=89ec1519928, topicName=RDN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4e013034210, createdName=xsm922, createdTime=Thu Apr 19 02:56:00 CST 2012, time=2012-04-19, status=1, ipAttribution=)]
    2012-04-19 xsm922

    #RDN#

    0